Shares Of Ranbaxy

The apex court on November 15, 2019 had held former Ranbaxy promoters guilty of contempt of court for violating its order asking them not to divest their shares in FHL.

Pharmaceutical giant Ranbaxy's ex-promoters Shivinder Singh and his older brother Malvinder Singh were arrested on Thursday in a Rs 740-crore fraud case.

The former promoters of pharmaceutical company Ranbaxy, Malvinder Mohan Singh and his brother Shivinder Mohan Singh, were told by the Supreme Court today that they could go to jail for disobeying orders to pay dues to Japanese firm Daiichi Sankyo. "We will go into the issue - why you violated our orders. We will send you to jail. We have given you ...

The Supreme Court on Friday ordered status quo with regard to the sale of controlling stakes of Fortis Healthcare to Malaysian IHH Healthcare Berhad by former Ranbaxy promoters and hospital operators -- Malvinder and Shivinder Singh.

The Delhi High Court Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million Singapore dollars, which he obtained by selling his shares in a company in violation of court's direction.

Fortis Healthcare shares fell nearly 5 per cent on Friday, while Religare Enterprises shares traded 1 per cent lower. Both Fortis and Religare shares were headed for a fourth straight day of losses.

The two drugmakers did not give any deadline for the issues to be resolved. Kotak analysts, however, estimate Sun Pharma's Halol site - a site it had owned before the Ranbaxy deal - could be cleared by the second half of 2016.

Sun Pharma shares fell over 3 per cent on Monday after India's biggest pharma company said it expects revenues and net profit to be adversely hit in the short term due to supply constraints at its Halol facility in Gujarat and high expenses arising out of Ranbaxy integration as well as remedial actions.

Shares of Sun Pharma gained as much as 2 per cent on Tuesday after Ranbaxy Pharmaceuticals, a unit of India's biggest pharma company, settled a patent litigation with Actavis over the generic version of Absorica, which is used to treat acne.

Shares of Strides Arcolab surged nearly 4 per cent to Rs 1,191 at its day's high after the Bangalore-based pharma company reached a deal with Sun Pharmaceutical Industries Ltd to buy two marketing divisions of erstwhile Ranbaxy Laboratories.

Analysts estimate a roughly 8-10 per cent hit to profit for the year as Sun Pharma struggles to fix manufacturing problems at one of its own key plants and those of Ranbaxy Laboratories, the troubled rival it bought last year.

Analysts say the benefits of this price hike will be visible from the second quarter of this financial year and can lead to earnings upgrade for the company. On an annualised basis price increases can boost Sun Pharma's revenues by $45 million, some estimates suggested.

Daiichi which had forayed into the Indian pharmaceutical market by buying a majority stake in Ranbaxy Laboratories in 2008 for Rs 22,000 crore, today sold over 21 crore shares in Sun Pharma.

Sun Pharmaceutical Industries has received approval from the Reserve Bank of India (RBI) for transfer of overseas investments of Ranbaxy to it and issue its shares to the non-resident shareholders of the latter as part of the $4-billion merger deal between the companies.

The Nifty opened flat on Tuesday. However, sentiment is likely to be positive as both foreign and domestic investors turned net buyers of Indian equities on Monday. Foreign investors bought shares worth Rs 417 crore while, domestic investors were net buyers to the tune of Rs 404 crore in cash market. Trading volume declined on Monday; cash segment ...

The apex court on November 15, 2019 had held former Ranbaxy promoters guilty of contempt of court for violating its order asking them not to divest their shares in FHL.

Pharmaceutical giant Ranbaxy's ex-promoters Shivinder Singh and his older brother Malvinder Singh were arrested on Thursday in a Rs 740-crore fraud case.

The former promoters of pharmaceutical company Ranbaxy, Malvinder Mohan Singh and his brother Shivinder Mohan Singh, were told by the Supreme Court today that they could go to jail for disobeying orders to pay dues to Japanese firm Daiichi Sankyo. "We will go into the issue - why you violated our orders. We will send you to jail. We have given you ...

The Supreme Court on Friday ordered status quo with regard to the sale of controlling stakes of Fortis Healthcare to Malaysian IHH Healthcare Berhad by former Ranbaxy promoters and hospital operators -- Malvinder and Shivinder Singh.

The Delhi High Court Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million Singapore dollars, which he obtained by selling his shares in a company in violation of court's direction.

Fortis Healthcare shares fell nearly 5 per cent on Friday, while Religare Enterprises shares traded 1 per cent lower. Both Fortis and Religare shares were headed for a fourth straight day of losses.

The two drugmakers did not give any deadline for the issues to be resolved. Kotak analysts, however, estimate Sun Pharma's Halol site - a site it had owned before the Ranbaxy deal - could be cleared by the second half of 2016.

Sun Pharma shares fell over 3 per cent on Monday after India's biggest pharma company said it expects revenues and net profit to be adversely hit in the short term due to supply constraints at its Halol facility in Gujarat and high expenses arising out of Ranbaxy integration as well as remedial actions.

Shares of Sun Pharma gained as much as 2 per cent on Tuesday after Ranbaxy Pharmaceuticals, a unit of India's biggest pharma company, settled a patent litigation with Actavis over the generic version of Absorica, which is used to treat acne.

Shares of Strides Arcolab surged nearly 4 per cent to Rs 1,191 at its day's high after the Bangalore-based pharma company reached a deal with Sun Pharmaceutical Industries Ltd to buy two marketing divisions of erstwhile Ranbaxy Laboratories.

Analysts estimate a roughly 8-10 per cent hit to profit for the year as Sun Pharma struggles to fix manufacturing problems at one of its own key plants and those of Ranbaxy Laboratories, the troubled rival it bought last year.

Analysts say the benefits of this price hike will be visible from the second quarter of this financial year and can lead to earnings upgrade for the company. On an annualised basis price increases can boost Sun Pharma's revenues by $45 million, some estimates suggested.

Daiichi which had forayed into the Indian pharmaceutical market by buying a majority stake in Ranbaxy Laboratories in 2008 for Rs 22,000 crore, today sold over 21 crore shares in Sun Pharma.

Sun Pharmaceutical Industries has received approval from the Reserve Bank of India (RBI) for transfer of overseas investments of Ranbaxy to it and issue its shares to the non-resident shareholders of the latter as part of the $4-billion merger deal between the companies.

The Nifty opened flat on Tuesday. However, sentiment is likely to be positive as both foreign and domestic investors turned net buyers of Indian equities on Monday. Foreign investors bought shares worth Rs 417 crore while, domestic investors were net buyers to the tune of Rs 404 crore in cash market. Trading volume declined on Monday; cash segment ...